Smith & Nephew plc SNN

NYSE | Technology | Medical technology and devices
Free
No email, no account, no signup.
Exchange
NYSE
Type
Technology
Sector
Medical technology and devices

Price & valuation

Last close
USD 30.01
2026-08-11
1 week
-0.4 %
3 months
+0.6 %
12 months
-17.2 %
From 52w high
-22.5 %
From 52w low
+4.5 %
We're already tracking Smith & Nephew plc — here are the latest events we've registered

Recent News

  • Following the Q1 update on 6 May 2026 (revenue $1.50bn; guidance unchanged), Smith & Nephew has initiated the first tranche of its new share buyback program ($250m, started 8 May 2026). Activist investor Cevian Capital has also increased its stake to above 11%. Otherwise, news flow has been dominated by smaller product/partnership items (incl. LEAF 3.0) and some analyst target/rating adjustments, with no new financial guidance.

Catalysts

7 Sep 2026 — End of first buyback tranche ($250m)

What Firelda Watch includes for Smith & Nephew plc

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — AI roundup of the week's news
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Smith & Nephew plc will be delivered in the same format.

Want to follow Smith & Nephew plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow 3 companies free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Smith & Nephew plc SNN
Smith & Nephew plc — this picture changes. Follow free
Follow Smith & Nephew plc free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.